Prefer Glenmark Pharma, Biocon over Divis Lab: SP Tulsian

SP Tulsian, sptulsian.com advises to prefer Glenmark Pharma and Biocon over Divis Lab.

Tulsian told CNBC-TV18, “I am not too convinced on Divi`s Labs particularly because firstly this has a very low tradability. So your impact cost is very high. Whenever you want to buy or sell, obviously impact costs are very high.” He further added, “If you make a comparative analysis, maybe stocks like Glenmark Pharma or maybe stocks like Biocon, Ranbaxy - they are looking better or maybe Aurobindo Pharma because the stock having corrected, probably I will look to make my buying list on those four stocks rather than Divi’s Lab.”